Company research
Passage BIO, Inc.
CIK 1787297Updated Nov 11, 2026
SecurityPASG · NASDAQ · equity
PASG price & chart
Loading TradingView…
NASDAQ:PASG on TradingView ↗About the company
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Passage Bio’s primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
EFFECT filing
424B3 filing
S-4/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 74,160,000Source | 111,752,000Source | 25,175,000Source | 79,198,000Source | 125,392,000Source | 36,462,000Source | 86,006,000Source | 140,531,000Source | 62,281,000Source | 102,412,000Source | 150,545,000Source | 243,549,000Source |
| Property, Plant and Equipment, NetUSD | 5,159,000Source | 10,036,000Source | — | 5,340,000Source | 13,054,000Source | 826,000Source | 5,523,000Source | 14,489,000Source | 4,107,000Source | 9,331,000Source | 15,295,000Source | 22,515,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 52,773,000Source | 32,292,000Source | 24,155,000Source | 57,626,000Source | 24,770,000Source | 33,336,000Source | 63,357,000Source | 36,773,000Source | 46,303,000Source | 37,573,000Source | 21,709,000Source | 34,601,000Source |
| Assets, CurrentUSD | 55,730,000Source | 87,216,000Source | 25,175,000Source | 60,315,000Source | 95,000,000Source | 34,741,000Source | 66,669,000Source | 108,293,000Source | 47,762,000Source | 78,815,000Source | 117,959,000Source | 197,044,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,637,000Source | 1,210,000Source | 768,000Source | 1,402,000Source | 1,397,000Source | 682,000Source | 2,121,000Source | 1,784,000Source | 629,000Source | 838,000Source | 923,000Source | 926,000Source |
| Operating Lease, Right-of-Use AssetUSD | 13,001,000Source | 14,037,000Source | — | 13,273,000Source | 16,822,000Source | 651,000Source | 13,540,000Source | 17,087,000Source | 10,168,000Source | 13,803,000Source | 16,858,000Source | 19,723,000Source |
| Other Assets, NoncurrentUSD | 270,000Source | 463,000Source | — | 270,000Source | 516,000Source | 244,000Source | 274,000Source | 662,000Source | 244,000Source | 463,000Source | 433,000Source | 4,267,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 43,040,000Source | 39,036,000Source | 20,719,000Source | 40,940,000Source | 34,835,000Source | 24,710,000Source | 39,300,000Source | 35,648,000Source | 43,526,000Source | 41,151,000Source | 39,262,000Source | 42,183,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | — | 6,000Source | — | — | 6,000Source | — | 6,000Source | 6,000Source | — | 6,000Source | 5,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 722,894,000Source | 719,188,000Source | 724,593,000Source | 722,283,000Source | 717,788,000Source | 724,068,000Source | 721,340,000Source | 716,125,000Source | 723,512,000Source | 720,482,000Source | 705,789,000Source | 694,733,000Source |
| Retained Earnings (Accumulated Deficit)USD | -691,774,000Source | -646,510,000Source | -720,137,000Source | -684,025,000Source | -627,170,000Source | -712,316,000Source | -674,640,000Source | -611,179,000Source | -704,757,000Source | -659,235,000Source | -594,468,000Source | -492,406,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 32,000Source | — | — | -67,000Source | — | — | -69,000Source | — | 8,000Source | -43,000Source | -966,000Source |
| Stockholders' Equity Attributable to ParentUSD | 31,120,000Source | 72,716,000Source | 4,456,000Source | 38,258,000Source | 90,557,000Source | 11,752,000Source | 46,706,000Source | 104,883,000Source | 18,755,000Source | 61,261,000Source | 111,283,000Source | 201,366,000Source |
| Liabilities and EquityUSD | 74,160,000Source | 111,752,000Source | 25,175,000Source | 79,198,000Source | 125,392,000Source | 36,462,000Source | 86,006,000Source | 140,531,000Source | 62,281,000Source | 102,412,000Source | 150,545,000Source | 243,549,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 22,245,000Source | 16,951,000Source | 20,719,000Source | 19,801,000Source | 12,385,000Source | 20,104,000Source | 17,825,000Source | 12,841,000Source | 23,083,000Source | 19,363,000Source | 16,341,000Source | 18,351,000Source |
| Operating Lease, Liability, CurrentUSD | 3,542,000Source | 3,733,000Source | — | 3,592,000Source | 3,701,000Source | 1,149,000Source | 3,641,000Source | 3,671,000Source | 3,567,000Source | 3,688,000Source | 3,373,000Source | 3,275,000Source |
| Accounts Payable, CurrentUSD | 952,000Source | 1,489,000Source | 902,000Source | 2,395,000Source | 621,000Source | 1,310,000Source | 1,458,000Source | 1,687,000Source | 1,113,000Source | 742,000Source | 1,298,000Source | 4,065,000Source |
| Operating Lease, Liability, NoncurrentUSD | 20,795,000Source | 22,085,000Source | — | 21,139,000Source | 22,450,000Source | 4,606,000Source | 21,475,000Source | 22,807,000Source | 20,443,000Source | 21,788,000Source | 22,921,000Source | 23,832,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 3,044,000Source | 4,445,000Source | 5,832,000Source | 8,422,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 200,000Source | 800,000Source | — | 200,000Source | 129,000Source | 201,000Source | 728,000Source | 3,081,000Source | 3,721,000Source | 3,679,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 556,000Source | 858,000Source | 3,001,000Source | 5,820,000Source | 10,921,000Source | 18,954,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,987,000Source | -13,847,000Source | -31,509,000Source | -47,956,000Source | -78,264,000Source | -118,210,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 20,000Source | 39,631,000Source | 40,216,000Source | 54,946,000Source | 65,237,000Source | 25,199,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 23,000Source | 8,874,000Source | 135,000Source | -1,353,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -12,967,000Source | 25,784,000Source | 8,730,000Source | 15,864,000Source | -12,892,000Source | -94,364,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 52,773,000Source | 32,292,000Source | 24,155,000Source | 57,626,000Source | 33,336,000Source | 63,357,000Source | 46,303,000Source | 37,573,000Source | 21,709,000Source | 34,601,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 611,000Source | 1,400,000Source | 525,000Source | 923,000Source | 556,000Source | 858,000Source | 3,001,000Source | 5,820,000Source | 10,921,000Source | 18,954,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | 800,000Source | — | 3,200,000Source | — | — | 0Source | -463,000Source | — |
| General and Administrative ExpenseUSD | — | — | 4,348,000Source | 7,251,000Source | 6,873,000Source | 4,520,000Source | 4,787,000Source | 6,085,000Source | 19,875,000Source | 24,988,000Source | 41,580,000Source | 49,341,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | -8,000Source | -8,000Source | 51,000Source | 923,000Source | -553,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,749,000Source | -19,340,000Source | -7,821,000Source | -9,385,000Source | -7,559,000Source | -15,405,000Source | -45,522,000Source | -64,767,000Source | -102,062,000Source | -136,125,000Source |
| Operating Lease, Impairment LossUSD | — | — | 0Source | 2,500,000Source | 0Source | 0Source | 0Source | 0Source | 2,633,000Source | 2,516,000Source | 2,185,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 906,000Source | 1,362,000Source | 451,000Source | 949,000Source | 688,000Source | 1,054,000Source | 3,774,000Source | 5,633,000Source | 6,327,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 35,000Source | — | 129,000Source |
| Gain (Loss) on Termination of Lease | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -8,655,000Source | -20,702,000Source | -8,272,000Source | -10,334,000Source | -8,247,000Source | -16,459,000Source | -49,296,000Source | -70,400,000Source | -108,389,000Source | -138,394,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 906,000Source | 1,362,000Source | 451,000Source | 949,000Source | 688,000Source | 1,054,000Source | 3,774,000Source | 5,633,000Source | 6,327,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,749,000Source | -19,340,000Source | -7,821,000Source | -9,385,000Source | -7,559,000Source | -15,405,000Source | -45,522,000Source | -64,767,000Source | -102,062,000Source | -136,125,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.44Source | -6.15Source | -2.44Source | -2.96Source | -2.36Source | -4.87Source | -14.35Source | -1.07Source | -1.86Source | -2.5Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.44Source | -6.15Source | -2.44Source | -2.96Source | -2.36Source | -4.87Source | -14.35Source | -1.07Source | -1.86Source | -2.5Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 3,178,710Source | 3,146,582Source | 3,208,744Source | 3,168,933Source | 3,205,866Source | 3,163,914Source | 3,172,870Source | 60,405,036Source | 54,743,490Source | 54,429,023Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 3,178,710Source | 3,146,582Source | 3,208,744Source | 3,168,933Source | 3,205,866Source | 3,163,914Source | 3,172,870Source | 60,405,036Source | 54,743,490Source | 54,429,023Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 4,348,000Source | 7,251,000Source | 6,873,000Source | 4,520,000Source | 4,787,000Source | 6,085,000Source | 19,875,000Source | 24,988,000Source | 41,580,000Source | 49,341,000Source |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 2,269,000Source |
| Research and Development ExpenseUSD | — | — | 4,307,000Source | 8,656,000Source | 3,343,000Source | 5,814,000Source | 4,093,000Source | 7,737,000Source | 23,276,000Source | 40,179,000Source | — | — |
Offerings
Registration 333-297601
Filing attachments
ny20077915x5_ex4-3.htm · S-4/A · 2026-09-21
EX-4.3 2 ny20077915x5_ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES OF THE COMPANY STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIE…
Read attachment ↗ny20077915x3_ex107.htm · S-4/A · 2026-09-03
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) PASSAGE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Ra…
Read attachment ↗ny20077915x1_ex107.htm · S-4 · 2026-07-21
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) PASSAGE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registr…
Read attachment ↗tm2618476d2_ex99-1.htm · 425 · 2026-06-24
Exhibit 99.1 Passage Bio and Remix Therapeutics Announce Merger Agreement Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers Concurrent oversubscribed $100 million private placement finan…
Read attachment ↗tm2618476d2_ex99-2.htm · 425 · 2026-06-24
Exhibit 99.2 CONFIDENTIAL Modulating RNA Processing TO TARGET THE UNDRUGGABLE Investor Presentation June 2026 CONFIDENTIAL 2 Disclaimers Important Information for Investors This confidential presentation (“Presentation”) is for informational purposes only and is being provided to interested partie s s olely in their capacity as potential investors for the purpose of evaluating a potential private offering of securities (the “Pu rpose”) by Remix Therapeutics, Inc. (collectively with its subsidi…
Read attachment ↗tm2618476d1_ex99-1.htm · 8-K · 2026-06-24
EX-99.1 9 tm2618476d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Passage Bio and Remix Therapeutics Announce Merger Agreement Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers Concurrent o…
Read attachment ↗